CHASE Study – Bachmann’s Bundle vs. Right Atrial Appendage Study
Principal Investigator: Seth J. Worley, MD
Collaborators: Douglas C. Gohn, MD & Ward Pulliam, MD
Sponsor: Medtronic, Inc
Objective: This study is to investigate whether chronic atrial pacing from the inter-atrial septum in the Bachmann’s Bundle region (BBR) will improve atrial function and ventricular filling compared to right atrial appendage (RRA) pacing.
ECOG 1Y03. The Master Pharmacogenetic and Genomic Studies
Principal investigator: Robert J. Gottlieb, MD
Collaborators: Hematology/Oncology Physicians of Lancaster
Sponsor: ECOG
Objective: This study will allow genomic analysis to be performed on patients treated in large group trials to seek markers of response for toxicity that will allow the group to better individualize the treatment of patients. It is a correlative trial with the purpose of collecting specimens, whole blood plasma or PMN, depending on the specific trial, from patients entered on therapeutic studies. The initial studies incorporated in ECOG 1Y03 are the pancreatic trials ECOG 6201 and ECOG 4201, which both of these studies are currently opened at the Lancaster General Hospital.
NSABP B-38. This is a Phase III adjuvant trial comparing 3 chemotherapy regimens in women with node-positive breast cancer--docetaxel, doxorubicin, and Cytoxan (TAC) versus dose-dense (DD) doxorubicin and Cytoxan, followed by DD paclitaxel (DDAC, followed by Taxol) versus DD doxorubicin and Cytoxan, followed by DD paclitaxel plus gemcitabine (DDAC, followed by PG).
Principal investigator: Robert J. Gottlieb, MD
Collaborators: Hematology/Oncology Physicians of Lancaster
Sponsor: National Surgical Adjuvant Breast and Bowel Project
Objective: To determine whether the dose-dense AC, followed by PG regimen is superior to the TAC regimen, as well as the dose-dense AC, followed by Taxol regimen in improving disease-free survival and to compare the relative disease-free survival of TAC and DDAC, followed by P. Secondary aims are to determine if dose-dense AC, followed by PG is superior to TAC, as well as dose-dense AC, followed by Taxol in improving overall survival, recurrence-free interval, and distant recurrence-free interval of the TAC and dose-dense AC, followed by Taxol regimens. Also to compare the toxicities of all three of these arms.
Z9001. This is a Phase III randomized double-blind study of adjuvant ST1571 (Gleevec) versus placebo in patients following the resection of primary gastrointestinal stromal tumor (GIST).
Principal investigator: Robert J. Gottlieb, MD
Collaborators: Hematology/Oncology Physicians of Lancaster
Sponsor: American College of Surgeons Oncology Group (ACOSOG)
Objective: This is a Phase III randomized double-blind and placebo controlled trial with a crossover designed for tumor recurrence. The primary objective is to ascertain if patients with GIST following resection or randomized to Gleevec have longer survival when compared to those randomized to a placebo. Secondary objectives include seeing if those randomized to Gleevec following primary resection have a longer recurrence-free survival, to test the safety and efficacy of Gleevec, and also obtaining blood and tissue samples for correlative analysis.
BiAtrial Pacing in CRT
Principal Investigator: Seth J. Worley, MD
Collaborators: Douglas C. Gohn, MD & Ward Pulliam, MD
Sponsor: Medtronic, Inc.
Objective: It is hypothesized that pacing both upper chambers of the heart can correct their dysynchrony, as CRT is able to do for the bottom chambers. The purpose of this study is to evaluate the effect of pacing both chambers at the same time (biatrial pacing) in patients who are receiving CRT for heart failure.